Actemra and Similar Medications Linked to Serious Infections in JIA Patients
A study recently published in Modern Rheumatology demonstrates a higher risk of serious infections for young people with juvenile idiopathic arthritis (JIA) when they are treated with “biologic” therapies, such as Actemra (tocilizumab). These infections can include a form of herpes as well as tuberculosis and a fungal infection known as systemic mycoses. Out of 80 study participants, 27 wound up contracting infections a total of 35 times.
Despite Patient Deaths Associated with Actemra, Drugmaker Genentech Continues to Seek Approval for Additional Indications
In Big Pharma's quest to increase sales and profits, it will continually seek new uses and markets for its products – even when those products have proven harmful to patients.
Potentially Dangerous Arthritis Drug Wins FDA Approval for Cancer Treatment Side Effect
Actemra (tocilizumab), an arthritis medication implicated in at least 1,100 patient deaths, has won FDA approval for the treatment of what is known as CAR-T cell-induced cytokine release syndrome.
Study Shows Actemra Is Superior to Steroids in Treating Blood Vessel Inflammation. Is the Study Trustworthy?
Last week, the New England Journal of Medicine published the results of a Phase 3 clinical trial which demonstrated the superiority of Actemra (tocilizumab) over steroidal medications for the treatment of a condition known as “giant cell arteritis” (GCA). Most commonly affecting white, post-menopausal women, this malady causes a constriction of the blood vessels, which in turn reduces blood flow.